Non-malignant late effects in lymphoma  patients treated with autologous hematopoietic  stem cell transplantation: Otolog hematopoietik kök hücre nakli yapılan lenfomalı  hastalarda malign olmayan geç etkiler

Pınar Sırmatel; Hülya  Yılmaz; Eren  Gündüz

doi:10.5152/EurJTher.2017.66

Authors

Pınar Sırmatel Department of Internal Medicine, Murat State Hospital
Hülya Yılmaz Department of Biostatistics, Eskişehir Osmangazi University, School of Medicine
Eren Gündüz Department of Hematology, Eskişehir Osmangazi University, School of Medicine

DOI:

https://doi.org/10.5152/EurJTher.2017.66

Keywords:

Lymphoma, autologous hematopoietic stem cell transplantation, non-malignant, late effect

Abstract

Objective: Developments in transplantation procedures have led to an increase in the number of long-term survivors after hematopoietic stem cell transplantation (HSCT). In this study, we investigated non-malignant late side effects after autologous HSCT (AHSCT) in lymphoma patients.
Methods: Patients were evaluated for immune system, eye, lung, heart, liver, kidney, and endocrine function tests.
Results: Nine (26%) patients had absolute lymphopenia. Cataract was the only eye complication. Four (11.4%) patients had obstructive- and 8 (22.9%) had restrictive-type pulmonary function abnormalities. Only one patient had symptomatic heart failure. One patient developed renal failure. Fifty-three percent of male patients described impotence. The most frequent endocrine disorder was hypothyroidism. Five (14.2%) patients had osteoporosis.
Conclusion: There is not enough data on the non-malignant late effects after AHSCT. Although the lack of a control group is a limitation of our study, our results emphasize the importance of following AHSCT patients for non-malignant late effects of transplantation.

Metrics

Metrics Loading ...

References

Majhail NS, Ness KK, Burns LJ, Sun CL, Carter A, Francisco L, et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant 2007; 13: 1153-9.

Wilczynski SW, Erasmus JJ, Petros WP, Vredenburgh JJ, Folz RJ. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med 1998; 157: 565-73.

Seiden MV, Elias A, Ayash L, Hunt M, Eder JP, Schnipper LE, et al. Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four

chemotherapy regimens. Bone Marrow Transplant 1992; 10: 57-63.

Carlson K, Bäcklund L, Smedmyr B, Oberg G, Simonsson B. Pulmonary function and complications subsequent to autologous bone marrow transplantation. Bone Marrow Transplant 1994; 14: 805-11.

Lane AA, Armand P, Feng Y, Neuberg DS, Abramson JS, Brown JR, et al. Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma 2012; 53: 1130-6.

Cerveri I, Zoia MC, Fulgoni P, Corsico A, Casali L, Tinelli C, et al. Late pulmonary sequelae after childhood bone marrow transplantation. Thorax 1999; 54: 131-5.

Tichelli A, Bhatia S, Socie G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol 2008; 142: 11-26.

Roziakova L, Mistrik M, Batorova A, Kruzliak P, Bojtarova E, Dubrava J, et al. Can we predict clinical cardiotoxicity with cardiac biomarkers in patients after haematopoietic stem cell transplantation? Cardiovasc Toxicol 2015; 15: 210-6.

Genberg M, Öberg A, Andrén B, Hedenström H, Frisk P, Flachskampf FA. Cardiac function after hematopoietic cell transplantation: an echocardiographic cross-sectional study in young adults treated in childhood. Pediatr Blood Cancer 2015; 62: 143-7.

Ruiz-Soto R, Sergent G, Gisselbrecht C, Larghero J, Ertault M, Hennequin C, et al. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients. Cancer 2005; 104: 2735-42.

Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter 2012; 34: 109-33.

Choi M, Sun CL, Kurian S, Carter A, Francisco L, Forman SJ, et al. Incidence and predictors of delayed chronic kidney disease in longterm survivors of hematopoietic cell transplantation. Cancer 2008; 113: 1580-7.

Moser EC, Noordijk EM, Carde P, Tirelli U, Baars JW, Thomas J, et al. Late non-neoplastic events in patients with aggressive non-Hodgkin’s lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma 2005; 6: 122-30.

Mertens AC, Ramsay NK, Kouris S, Neglia JP. Patterns of gonadal dysfunction following bone marrow transplantation. Bone Marrow Transplant 1998; 22: 345-50.

Schimmer AD, Ali V, Stewart AK, Imrie K, Keating A. Male sexual function after autologous blood or marrow transplantation. Biol Blood Marrow Transplant 2001; 7: 279-83.

Thomas O, Mahé M, Campion L, Bourdin S, Milpied N, Brunet G, et al. Long-term complications of total body irradiation in adults. Int J Radiat Oncol Biol Phys 2001; 49: 125-31.

Majhail NS, Ness KK, Burns LJ, Sun CL, Carter A, Francisco L, et al. Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study. Biol Blood Marrow Transplant 2007; 13: 1153-9.